1. Dixon, L, Postrado, L, Delahanty, J, Fischer, PJ, Lehman, A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis. 1999; 187(8): 496–502.
3. De Hert, MA, van Winkel, R, Van Eyck, D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83(1): 87–93.
4. Laursen, TM, Munk-Olsen, T, Vestergaard, M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry. 2012; 25(2): 83–88.
5. Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35(1): 51–68.
6. Weiden, PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13(1): 13–24.
8. Durgam, S, Earley, W, Lipschitz, A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016; 173(3): 271–281.
9. Durgam, S, Earley, W, Guo, H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016; 77(3): 371–378.
10. Németh, G, Laszlovszky, I, Czobor, P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017; pii: S0140-6736(17): 30060-0. Epub ahead of print Feb 6.
11. Kiss, B, Horváth, A, Némethy, Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010; 333(1): 328–340. Available at: http://jpet.aspetjournals.org/content/333/1/328.
12. Kiss, B, Horti, F, Bobok, A. Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res. 2012; 136(8 Suppl 1): S190.
13. Slifstein, M, Abi-Dargham, A, D’Souza, DC, et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]–(+)–PHNO. Neuropsychopharmacology. 2013; 38: S520–S521.
14. Seneca, N, Finnema, SJ, Laszlovszky, I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011; 218(3): 579–587. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210913/.
16. Durgam, S, Cutler, AJ, Lu, K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase III, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015; 76(12): e1574–e1582. Available at: http://www.psychiatrist.com/jcp/article/Pages/2015/v76n12/v76n1201.aspx.
17. Kane, JM, Zukin, S, Wang, Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015; 35(4): 367–373.
18. Durgam, S, Greenberg, W, Li, D, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology (Berl). 2017; 234(2): 199–209. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203812/.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM–IV–TR). Washington, DC: American Psychiatric Association; 2000.
20. Kay, SR, Opler, LA, Spitzer, RL, Williams, JB, Fiszbein, A, Gorelick, A. SCID–PANSS: two-tier diagnostic system for psychotic disorders. Compr Psychiatry. 1991; 32(4): 355–361.
21. Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13(2): 261–276.
22. Guy, W. The Clinician Global Severity and Impression Scales: ECDEU Assessment Manual for Psychopharmacology. DHEW Publication no. 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218–222.
23. Posner, K, Brown, GK, Stanley, B, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12): 1266–1277. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893686/.
24. Guy, W. The Abnormal Movement Scale: ECDEU Assessment Manual for Psychopharmacology. DHEW Publication no. 76-338. Rockville, MD: National Institute of Mental Health; 1976: 218–222.
25. Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154: 672–676.
26. Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212: 11–19.
28. Chrzanowski, WK, Marcus, RN, Torbeyns, A, Nyilas, M, McQuade, RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 2006; 189(2): 259–266.
29. Cutler, AJ, Kalali, AH, Mattingly, GW, Kunovac, J, Meng, X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013; 18(1): 43–54.
30. Kane, JM, Fleischhacker, WW, Hansen, L, Perlis, R, Pikalov, A 3rd, Assunção-Talbott, S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009; 70(5): 627–643.
31. Keks, NA, Ingham, M, Khan, A, Karcher, K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007; 191(2): 131–139. Available at: http://bjp.rcpsych.org/content/191/2/131.
32. Arato, M, O’Connor, R, Meltzer, H, ZEUS Study Group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) Study. Int Clin Psychopharmacol. 2002; 17(5): 207–215.
33. Fleischhacker, WW, McQuade, RD, Marcus, RN, Archibald, D, Swanink, R, Carson, WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65(6): 510–517.
34. Stahl, SM, Cucchiaro, J, Simonelli, D, Hsu, J, Pikalov, A, Loebel, A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013; 74(5): 507–515. Available at: http://www.psychiatrist.com/JCP/article/Pages/2013/v74n05/v74n0516.aspx.
35. Citrome, L, Cucchiaro, J, Sarma, K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012; 27(3): 165–176.
36. Newcomer, JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 8(Suppl 1): 20–27.
38. Lee, SY, Park, MH, Patkar, AA, Pae, CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(2): 490–496.